key: cord-0274691-xjc0l0tv
authors: de Gier, B.; Kooijman, M.; Kemmeren, J.; de Keizer, N.; Dongelmans, D.; van Iersel, S. C. J. L.; van de Kassteele, J.; Andeweg, S. P.; the RIVM COVID-19 epidemiology and surveillance team,; de Melker, H. E.; Hahne, S. J. M.; Knol, M. J.; van den Hof, S.
title: COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April- August 2021
date: 2021-09-17
journal: nan
DOI: 10.1101/2021.09.15.21263613
sha: 247c757fb0e99830fa9e90225d14c289f52be737
doc_id: 274691
cord_uid: xjc0l0tv

The objective of this study was to estimate vaccine effectiveness (VE) against COVID-19 hospitalization and ICU admission, per period according to dominating SARS-CoV-2 variant (Alpha and Delta), per vaccine, and per time since vaccination. To this end, data from the national COVID-19 vaccination register was added to the national register of COVID-19 hospitalizations. For the study period 4 April- 29 August 2021, 15,571 hospitalized people with COVID-19 were included in the analysis, of whom 887 (5.7%) were fully vaccinated. Incidence rates of hospitalizations and ICU admissions per age group and vaccination status were calculated, and VE was estimated as 1-incidence rate ratio, adjusted for calendar date and age group in a negative binomial regression model. VE against hospitalization for full vaccination was 94% (95%CI 93-95%) in the Alpha period and 95% (95%CI 94-95%) in the Delta period. The VE for full vaccination against ICU admission was 93% (95%CI 87-96%) in the Alpha period and 97% (95%CI 97-98%) in the Delta period. VE was high in all age groups and did not show waning with time since vaccination up to 20 weeks after full vaccination.

Delta infection (6) (7) (8) . However, a more important question is whether vaccine effectiveness against severe COVID-19 resulting in hospitalization or even ICU admission has diminished since the emergence of the Delta variant. Also, monitoring the possible waning of vaccineinduced immunity against severe COVID-19 is vital to estimate the burden on health care during autumn and winter 2021-2022, and to appraise the need for additional interventions such as booster doses.

In this study, we estimate incidence rates of COVID-19 hospitalizations and ICU admissions by vaccination status and age group to calculate vaccine effectiveness against COVID-19 hospitalizations and ICU admissions by age group, vaccine type, time since vaccination, and prevailing variant (Alpha or Delta).

The number of hospitalizations and ICU admissions per vaccination status per day (the numerator) is based on a nationwide registry of COVID-19 hospitalizations (NICE)(9), linked to vaccination data from the national COVID-19 vaccination registry (CIMS), using the social services number as key to link the data. On request of the government all hospitalized persons with a positive SARS-CoV-2 test or CT-confirmed COVID-19 are registered in the NICE COVID-19 registry, a minimal dataset is made available to the RIVM for public health surveillance. For each person, the first admission date since June 2020 was included. In the Netherlands, every vaccinated person is asked for informed consent to have their vaccination data centrally registered in CIMS (COVID vaccination information and monitoring system). Therefore CIMS does not provide a complete registry of all administered COVID-19 vaccines. For people who are not registered as vaccinated in CIMS, we cannot be certain whether they are unvaccinated or whether they did not give informed consent. Of people . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint supplemented with CIMS data for vaccinations by others, such as general practitioners and hospitals. The number of partly and fully vaccinated persons per age group and day was subtracted from the population size to calculate the size of the unvaccinated population.

Vaccination status was defined as 'partly vaccinated' 14 days after a first vaccine dose and becomes 'fully vaccinated' 14 days after a second dose or 28 days after the Janssen 1-dose schedule. People who received no vaccine or one dose less than 14 ago are categorized as unvaccinated. For hospitalized patients, the vaccination status on the date of disease onset was determined. The NICE data does not contain disease onset dates. Therefore, the median number of days between disease onset and admission date per age group (ranging between 3-7 days) was retrieved from the national notification database Osiris-AIZ and applied to admission dates in NICE to estimate disease onset dates. The dataset included hospitalizations with admission dates until September 5, for this analysis we included hospitalizations with an estimated date of disease onset up to August 29, 2021.

Incidence rates per 10.000 person-days were calculated by dividing the number of hospitalizations and ICU admission by the population size, per vaccination status. Incidence rate ratio's (IRR) and 95% confidence intervals (95%CI) were estimated with a negative binomial regression model with log-link function, to allow for overdispersion in the numbers.

The number of hospitalizations or ICU admissions was the dependent variable, vaccination status, 5-year age group and calendar dates were independent variables. Calendar date was included as penalized spline to model the non-linear effect of time on incidence rates. The logarithm of population size was included as offset. Vaccine effectiveness (VE) was calculated as 1-IRR x 100%.

All VE estimates were stratified in two periods, when a variant of concern (VOC) was clearly dominant in the Netherlands. The Alpha period is 4 April 2021-29 May 2021, when over 95% of weekly sequenced SARS-CoV-2 isolates pertained the Alpha variant. The Delta period is 4 July 2021 -29 August 2021, which is the end of the study period, with 99.9% of all sequenced isolates pertaining the Delta variant (5).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted September 17, 2021. ; https://doi.org/10.1101/2021.09.15.21263613 doi: medRxiv preprint Table 2 shows the estimated VE per age group per vaccine, for the Delta period. Because of small numbers of fully vaccinated hospitalizations during the Alpha period, we do not present VE by vaccine type for this period. High VE are found for all four vaccines, with the exception of Spikevax in the oldest age group. Please note that in the Netherlands, persons with a medical condition putting them at high risk of severe COVID-19 were specifically given the Spikevax vaccine. The Janssen vaccine is not allocated to elderly in the Netherlands, therefore no VE for ≥70 was estimated. Table 3 shows the VE by time since the 'fully vaccinated' state was reached, in 5-week periods. No indication for VE waning is observed up to 20 weeks after full vaccination. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

This study using nationwide surveillance data found 95% and 97% effectiveness of the (11) . In our data, adjusting for 5-year age groups, we did not observe such waning up to 20-plus weeks after full vaccination. Close monitoring of VE against severe disease by time since vaccination is important to timely detect a possible need for additional intervention such as booster doses.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Because of this incompleteness, some patients without vaccination records in CIMS might be misclassified as unvaccinated. This could lead to an overestimation of VE. We explored the possible influence of this misclassification on our estimates with a simple sensitivity analysis, assuming misclassification of 7.3% of all truly vaccinated cases as unvaccinated.

This reduced the VE estimates by only 1 -2%.

A limitation of the method used is that previously infected persons who have developed natural immunity are not removed from the person-time at risk. A recent study showed that 20-25% of Dutch blood donors has acquired immunity through infection (16) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 17, 2021. ; https://doi.org/10.1101/2021.09. 15.21263613 doi: medRxiv preprint In conclusion, the COVID-19 VE against hospitalization and ICU admissions are very high in the Netherlands, also in the period when the Delta variant dominates and up to 20 weeks after full vaccination. The observed lower protection of persons vaccinated with the Spikevax vaccine is likely a result of the allocation of this vaccine to the population at medical high risk of severe COVID-19 and of vaccine breakthrough infection. Additional interventions might be needed to protect this vulnerable group against severe COVID-19. Among the unvaccinated population, the incidence of COVID-19 hospitalizations and ICU admissions is high, which, combined with the size of this population, could lead to a significant strain on health care in the coming months. A further increase in vaccination coverage is key to reduce the burden on health care.

This work was funded by the Dutch Ministry of Health, Welfare and Sports.

on the COVID-19 vaccination programme: RIVM

COVID-19 vaccinations: Ministry of Health, Welfare and Sport

Effectiveness and impact of COVID-19 vaccination in the elderly, the Netherlands

Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands

Coronavirus variants: Dutch government

Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence

Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine; Preliminary Study

Progress of the Delta variant and erosion of vaccine effectiveness, a warning from Utah

National Intensive Care Evaluation

European Centre for Disease Prevention and Control. Interim public health considerations for the provision of additional COVID-19 vaccine doses

Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted

Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States

Effectiveness of COVID-19 vaccines against variants of concern

The Hague: House of representatives

Amsterdam inhabitants with migration background hit harder by coronavirus

Non-Western migrants relatively often in hospital with corona: 'Time for action

The data used in this study are collected, maintained and disclosed by the MHS (GGDen), GGDGHOR Nederland, RIVM Dienst Vaccinvoorziening en Preventie, all Dutch hospitals and the NICE regsitration. 

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint